Eric P. Krenning

33.9k citations
277 papers · 22.6k · 9 hit papers · h-index 83

Impact in

  • Neurology top 0.02%
    • Neuroblastoma Research and Treatments
  • Oncology top 0.05%
    • Lung Cancer Research Studies
    • Pancreatic and Hepatic Oncology Research
    • Peptidase Inhibition and Analysis

Papers in

    • Neuroendocrine Tumor Research Advances 187
    • Lung Cancer Research Studies 124
    • Peptidase Inhibition and Analysis 19

Eric P. Krenning

275 papers receiving 22.0k citations

Eric P. Krenning's Hit Papers

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial 2018 · 272 citations
2720+11+23Years since publication4008001.2k

Peers

Eric P. Krenning
Comparison fields: 5 of 162
  • Neurology 9.4k
  • Oncology 12.5k
  • Epidemiology 14.5k
  • Radiology, Nuclear Medicine and Imaging 6.9k
  • Endocrinology, Diabetes and Metabolism 2.8k
Replace E. P. Krenning with:
E. P. Krenning Netherlands
Marion de Jong Netherlands
Wouter W. de Herder Netherlands
Casper H.J. van Eijck Netherlands
Rodney J. Hicks Australia
Richard P. Baum Germany
Andreas K. Buck Germany
Anders Sundin Sweden
Martin Schlumberger France
Domenico Rubello Italy
Eric P. Krenning relative to E. P. Krenning Netherlands E. P. Krenning's profile →
Citations per field
00.5×3.1×
E. P. Krenning · 1×
Citations per year

Countries citing papers authored by Eric P. Krenning

Since Specialization
Citations

This map shows the geographic impact of Eric P. Krenning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric P. Krenning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric P. Krenning more than expected).

Fields of papers citing papers by Eric P. Krenning

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric P. Krenning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric P. Krenning. The network helps show where Eric P. Krenning may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric P. Krenning, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric P. Krenning Line = papers co-authored together Eric P. Krenning links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 277 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Gastroenteropancreatic neuroendocrine tumours
Hit paper breakdown →
20081221
2
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
Hit paper breakdown →
20081093
3
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
Hit paper breakdown →
1991680
4
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
Hit paper breakdown →
2012616
5
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
Hit paper breakdown →
2005517
6
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Hit paper breakdown →
2017416
7 1997394
8 2001368
9 2009355
10 2002328
11
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Hit paper breakdown →
2014328
12 2001305
13
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
Hit paper breakdown →
2017303
14 1997272
15
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
2005272
16
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
Hit paper breakdown →
2018272
17 2009268
18 2002260
19
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
2005255
20 1989251

About Eric P. Krenning

Eric P. Krenning is a scholar working on Epidemiology, Oncology, Radiology, Nuclear Medicine and Imaging, Neurology and Endocrinology, Diabetes and Metabolism, having authored 277 papers that have together received 22.6k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (187 papers), Lung Cancer Research Studies (124 papers), Radiopharmaceutical Chemistry and Applications (95 papers), Neuroblastoma Research and Treatments (95 papers), Medical Imaging Techniques and Applications (22 papers), Peptidase Inhibition and Analysis (19 papers), Neuropeptides and Animal Physiology (18 papers) and Cardiac Imaging and Diagnostics (15 papers). The work is most often cited by research in Neurology (9.4k citations), Oncology (12.5k citations), Epidemiology (14.5k citations), Radiology, Nuclear Medicine and Imaging (6.9k citations) and Endocrinology, Diabetes and Metabolism (2.8k citations). Eric P. Krenning has collaborated with scholars based in Netherlands, United States and Greece. Frequent co-authors include Dik J. Kwekkeboom, Marion de Jong, Wouter W. de Herder, Roelf Valkema, Boen L.R. Kam, Jean–Claude Reubi, Jaap J.M. Teunissen, P.P.M. Kooij, Willem H. Bakker and Martijn van Essen. Their work appears in journals such as European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, Journal of Clinical Oncology, Cancer Biotherapy and Radiopharmaceuticals and Neuroendocrinology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact